Research Articles - Other Retinal Diseases
The Foundation Fighting Blindness is providing $600,000 to a consortium of Israeli scientists working toward the ambitious goal of recruiting and genetically screening every person in Israel with an inherited retinal degenerative disease.
Thanks to a Foundation Fighting Blindness collaboration with GE Lighting, people accessing services at the Spectrios Institute for Low Vision in Wheaton, Illinois, now have significant lighting improvements at their disposal. A “re-lamping” effort, courtesy of GE Lighting, replaced much of the institute’s existing lighting with energy-efficient products and fixtures throughout the facility’s training, exam and counseling rooms, among other areas.
Three years after it began, the landmark Phase I gene therapy clinical trial for people with Leber congenital amaurosis (LCA) at the Universities of Pennsylvania and Florida continues to go very well. Overall safety and vision improvements have been sustained. All 15 participants in the study, ranging in age from 11 to 30, have demonstrated vision improvement to varying degrees, including increases in visual field, night vision and mobility. Improvements in visual acuity only
A Foundation-funded University of Wisconsin research team led by Dr. David Gamm has achieved a significant milestone in developing stem cell treatments for saving and restoring vision in people with retinal degenerations. For the first time, the scientists used stem cells derived from blood to produce multiple layers of cells that resemble retinal tissue. Most important, these cellular structures have some of the characteristics considered necessary for vision.
<p>Contrary to its name, Best disease is not a condition anyone wants. Named after the German ophthalmologist Friedrich Best more than a century ago, it is an inherited form of macular degeneration that can cause significant and progressive loss of central vision in children and adults.<br /><br />But thanks to a newly developed human model of the disease — derived from the skin of two affected patients — researchers have a new tool to study the condition and help develop treatment approaches that might save vision.
The study’s lead investigators, Andras Komaromy, D.V.M., Ph.D., and Gustavo Aguirre, V.M.D., Ph.D., presented the results of their FFB-funded achromatopsia study in April 2008 at the annual conference of the Association for Research in Vision and Ophthalmology.
A research team led by Robert Molday, Ph.D., at the University of British Columbia in Vancouver, has moved a step closer to developing a gene therapy for people with Leber congenital amaurosis (LCA) caused by mutations in the gene RD3. The investigators used an RD3 replacement gene therapy to restore photoreceptor function in mice with the condition, and plan to test the treatment in canines with RD3 mutations. Results of their
Continuing its role of fostering collaboration and knowledge-sharing to accelerate the clinical development of retinal disease therapies, the Foundation Fighting Blindness Clinical Research Institute (FFB CRI) co-hosted its Sixth Annual Orange County Innovation Symposium on February 27. This year’s event took place at the Gavin Herbert Eye Institute (GHEI), University of California, Irvine (UCI), which also served as co-host. William Link,